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Abstract
Background: Interstitial lung disease in systemic sclerosis (SSc-ILD) is a major cause of SSc-related death.
Imunosuppressive treatment (IS) is used in patients with SSc for various organ manifestations mainly to ameliorate
progression of SSc-ILD. Data on everyday IS prescription patterns and clinical courses of lung function during and
after therapy are scarce.
Methods: We analysed patients fulfilling American College of Rheumatology (ACR)/European League against
Rheumatism (EULAR) 2013 criteria for SSc-ILD and at least one report of IS. Types of IS, pulmonary function
tests (PFT) and PFT courses during IS treatment were evaluated.
Results: EUSTAR contains 3778/11,496 patients with SSc-ILD (33%), with IS in 2681/3,778 (71%). Glucocorticoid
(GC) monotherapy was prescribed in 30.6% patients with GC combinations plus cyclophosphamide (CYC) (11.9%),
azathioprine (AZA) (9.2%), methotrexate (MTX) (8.7%), or mycophenolate mofetil (MMF) (7.3%). Intensive IS (MMF
+ GC, CYC or CYC + GC) was started in patients with the worst PFTs and ground glass opacifications on imaging.
Patients without IS showed slightly less worsening in forced vital capacity (FVC) when starting with FVC 50–75%
or >75%. GC showed negative trends when starting with FVC <50%. Regarding diffusing capacity for carbon monoxide
(DLCO), negative DLCO trends were found in patients with MMF.
Conclusions: IS is broadly prescribed in SSc-ILD. Clusters of clinical and functional characteristics guide individualised
treatment. Data favour distinguished decision-making, pointing to either watchful waiting and close monitoring in the
early stages or start of immunosuppressive treatment in moderately impaired lung function. Advantages of specific IS
are difficult to depict due to confounding by indication. Data do not support liberal use of GC in SSc-ILD.
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Background
Interstitial lung disease (ILD) in systemic sclerosis
(SSc-ILD) is caused by alveolitis-induced fibrosis of
the intra-alveolar tissue, leading to progressive decline
in lung function [1]. It is the most frequent cause of
SSc-associated death [2]. Current treatment options
aim at reducing pulmonary interstitial inflammation
in order to prevent progression of fibrosis and con-
secutive deterioration of lung function.
Cyclophosphamide (CYC) is widely used in the treat-
ment of SSc-ILD, especially in induction therapy as
reflected by the European League Against Rheumatism
(EULAR) recommendations for SSc-ILD treatment [3].
Unfortunately, the toxicity of CYC makes it unsuitable
for long-term use. Furthermore, within the first sclero-
derma lung study, the effect of CYC waned a few
months after cessation [4]. Mycophenolate mofetil
(MMF) has been suggested as an alternative for induc-
tion and maintenance IS [5] and has been shown to sta-
bilise lung function in two studies [6, 7]. There are
recent data from the scleroderma lung study II on the
risks and benefits of a 2-year course of MMF versus a 1-
year course of oral CYC. Herein, MMF displayed a bet-
ter safety profile and a 1-year course of CYC improved
skin and lung function to a comparable extent [8].
Azathioprine (AZA) reflects the common practice of
introducing a steroid-sparing anti-rheumatic agent in
patients with idiopathic pulmonary fibrosis yet might be
rather harmful [9]. In SSc-ILD, the evidence for AZA is
inconclusive [10–12]. Methotrexate (MTX) is recom-
mended for treatment of skin manifestations in early dif-
fuse cutaneous SSc (dcSSc) [13]. Its use in SSc-ILD
remains controversial as lung fibrosis is a rare but po-
tentially severe side effect [14] and evidence for anti-
fibrotic efficacy in the lungs is lacking. As skin and lung
involvement may appear simultaneously, MTX is some-
times prescribed in SSc-ILD. Rituximab (RTX) is among
the most frequently used biological agents in SSc with a
recent case-control study and an observational study
suggesting beneficial effects on lung function [15]. As el-
evated interleukin-6 (IL-6) in SSc-patients has been as-
sociated with higher incidence of progressive pulmonary
decline, tocilizumab (TCZ) was recently introduced as a
therapeutic strategy within the faSScinate study [16, 17].
This randomised controlled trial demonstrated a benefit
from TCZ, with a significantly smaller decline in forced
vital capacity (FVC); unfortunately, this effect waned at
48 weeks. Low-dose glucocorticoids (GCs) used to be
the standard treatment for SSc-ILD. This is remarkable
as GCs have never been shown to improve ILD out-
comes and are suspected to dose-dependently increase
the risk of SSc renal crisis [18]. GCs are variously pre-
scribed at least initially in combination therapy in severe
and progressive ILD [13, 19]. Overall, current evidence
does not allow convincing recommendations on the use
of IS in ILD. The updated EULAR/European League
against Rheumatism Scleroderma Trial and Research
(EUSTAR) guidelines will be in line with this conclusion
[20].
The EUSTAR database offers a unique opportunity to
analyse IS therapy in SSc-ILD. The aims of this study
were (1) to analyse current use of IS drugs, (2) to test
correlation between drug use and lung function tests
and (3) to define specific treatments for defined disease
characteristics.
Methods
We included patients aged ≥ 18 years fulfilling the
American College of Rheumatology (ACR) 1980 or
ACR/EULAR 2013 classification criteria for SSc [21]
with signs of ILD on pulmonary high resolution com-
puted tomography (HRCT) and/or chest x-ray and at
least one report on IS.
Data analysis comprised first EUSTAR documentation
from 2004 until 6 May 2014. The entire observation
period of each patient since initial diagnosis of ILD was
considered. In order to receive comprehensive overviews
of IS in SSc-ILD we referred to all documented visits at
which IS was used. Missing IS information was counted
as “never IS” if at least one item from the list of im-
munosuppressive therapies was answered. Patients with
IS therapy (“ever IS”) at any time were compared to
patients who had never received IS (“never IS”). For our
analysis of “never IS” versus “ever IS” patients were in-
cluded at the visit when IS was documented for the first
time or time of first ILD documentation for “never IS”.
For comparison of the features of patients receiving dif-
ferent IS we selected patients with at least one follow up
since the documentation of ILD. We then grouped pa-
tients according to forced vital capacity (FVC) and dif-
fusing capacity of the lung for carbon monoxide
(DLCO) at the initiation of therapy, mimicking the clas-
sification by Steen [22] in order to generate three groups
with different SSc-ILD severity: “mild” for DLCO >60%
and FVC >85%, “moderate” for DLCO 51–60% and FVC
80–85% and “severe” for DLCO <51% and FVC <80%.
Standard EUSTAR documentation comprises current
history, past medical history, medications, physical
examination including modified Rodnan skin score
(mRSS), laboratory results, lung and heart function tests,
radiological imaging and capillaroscopy [23]. Disease
duration is calculated from the time since first non-
Raynaud’s symptom. Yearly follow-up documentation is
recommended. As a EUSTAR rule, each participating
centre must obtain an ethics vote from their respective
ethics committee. Afterwards, participating patients
need to sign an individual consent form prior to inclu-
sion into EUSTAR analysis.
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Statistics
Continuous parameters were compared by the Mann-
Whitney test, frequencies by the chi2 or Fisher exact
test; p values <0.05 were considered significant. No ad-
justment for multiple testing was done. Course of lung
function under treatment was evaluated by linear regres-
sion analysis of change in DLCO and FVC from treat-
ment start to at least one follow-up measurement.
Patients were grouped by ranges of starting values
(<50%, 50–75% and >75% predicted). Due to small num-
bers of cases for many treatment combinations, no indi-
vidual combinations could be considered. Instead,
additive and multiplicative effects of single drugs on the
overall group trend were tested within each stratum:
with additive effects indicating patients were taking that
drug over the same overall time trend, but at a higher or
lower level, meaning better or worse initial lung func-
tion, but afterwards the same course of DLCO or FVC;
and with multiplicative effects signalling a steeper slope
of the trend for patients using that drug, meaning either
a better or worse course than the overall trend. We
adjusted for the potential confounders of sex, age, extent
of skin involvement, disease duration and initial DLCO
or FVC values, respectively. Statistical analyses were per-
formed using IBM SPSS Statistics, version 19.
Results
Patients on IS have more severe and active ILD compared
to those without IS
Epidemiological data are shown in Table 1. Overall, IS
was used in 2681/3778 (71%) patients with SSc-ILD, but
only in 39.8% of patients with SSc without ILD (p < 0.05,
data not shown).
IS is used in a wide variety of monotherapy or
combination therapy
Frequencies of immunosuppressants ever used and high-
est therapy combinations ever used per patient are
shown in Fig. 1. Of the patients taking GC therapy, the
average prednisone dosage was > 10 mg/day in 17%,
and > 20 mg/day in 5.3% of patients.
Individual treatment regimens are shown in Fig. 2,
with more than 3 immunosuppressive drugs being ex-
ceptions (n = 17 patients, not shown).
Intensive IS is reserved for patients with severe and
active ILD
Patient characteristics at the start of the most frequent
monotherapy and combination therapy are described in
Table 2.
Compared to patients in the never IS group, patients
receiving GC monotherapy had significantly higher
prevalence of SSc-related organ complications except for
pulmonary hypertension and renal crisis. Within the
“ever IS” group, patients receiving GC monotherapy
were the oldest and had the longest disease duration.
Patients who took MTX were only slightly different from
patients in the never IS group. Patients who took MTX/
GC had significantly worse DLCO, forced expiratory vol-
ume in one second (FEV-1) and modified Rodnan skin
score (mRSS), indicating more severe disease and pos-
sibly also concomitant obstructive pulmonary disease.
Patients who took AZA had significant impairment in
FVC and DLCO, but no differences in New York Heart
Association (NYHA) class. Interestingly, they had lower
mRSS values than the never IS group. AZA/GC was
used in patients with a more prominent reduction in
DLCO and FVC values and with more patients in
NYHA III and IV than in AZA monotherapy. Patients
who took MMF had severe impairment of FVC and
DLCO, which was even more pronounced when GC was
added to MMF. Values for DLCO and FVC were lower
and severe NYHA classification more frequent than in
MMF monotherapy. Patients who took CYC had the
most severely impaired lung function and highest rate of
restrictive lung disease. Patients receiving MTX mono-
therapy had the best values for DLCO, FVC (p < 0.001)
and total lung capacity (TLC), lowest prevalence of pul-
monary hypertension (p < 0.05) and shortest disease dur-
ation. In contrast, patients who took CYC monotherapy
had worst impairment in lung function and the highest
rates of ground glass opacifications on imaging, plus the
most severe skin fibrosis and highest mRSS values.
A cluster of lung function parameters is associated with
specific choices of IS
Sorting different therapy arms by average impairment in
FVC and DLCO revealed clusters of ranges of lung func-
tion. Consequently, we grouped patients based on mean
FVC and DLCO according to the classification of Steen
[22]. Group I (mild impairment) had FVC of 86.9% and
DLCO of 60.8%; group II (moderate impairment) had
FVC of 83.4% and DLCO of 56.7%; and group III (severe
impairment) had FVC of 76.6% and DLCO of 49.6%.
Next we assessed whether other parameters were associ-
ated with specific choices of IS (Fig. 3).
Patients in group III had the worst FVC and DLCO,
highest mRSS values, worst NYHA class and the highest
rates of ground glass opacifications and restrictive
defects. Compared to patients in the never IS group, pa-
tients in all three groups had significantly worse FVC,
DLCO and TLC and more frequent ground glass opacifi-
cations. Patients in groups II and III had more severe
NYHA class (both p < 0.001).
Compared to patients in the never IS group, the rate
of ground glass opacification rates (24.4%) was twice that
in groups I and II (43.9% and 40.2%, respectively), and
even more often in group III (54.3%, all treatment
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Table 1 Characteristics of patients with SSc-ILD never or ever using immunosuppressive therapy
Total Never used IS therapy Ever used IS therapy P value
Number of patients 3778 1097 (29%) 2681 (71%)
Age (mean, SD) 55.5 ± 13.4 59.0 ± 13.6 54.0 ± 13.0 <0.001
Female 83.6% 86.5% 82.4% 0.002
BMI (mean, SD) (n = 1901) 24.6 ± 4.7 24.5 ± 5.1 24.7 ± 4.6 n.s.
Duration of SSc, years (mean, SD) 8.5 ± 7.9 10.8 ± 9.2 7.6 ± 7.1 <0.001
(median (IQR)) 6.2 (2.8; 11.9) 8.4 (4.3; 15.0) 5.4 (2.4; 10.8)
mRSS (n = 3515)
(mean, SD) 10.6 ± 8.7 8.9 ± 7.6 11.3 ± 9.0 <0.001
(median (IQR)) 8.0 (4.0; 17.0) 7.0 (4.0; 17.0) 9.0 (4.0; 17.0)
Extent of skin involvement (n = 3713)
diffuse 44.4% 29.4% 50.3%
limited 46.9% 60.9% 41.3% <0.001
sclerodactyly only 7.5% 7.4% 7.6%
none 1.2% 2.4% 0.8%
Present scleroderma pattern (n = 1081) 92.6% 92.3% 92.7% n.s.
active 40.7% 41.5% 40.4%
early 21.1% 25.3% 19.4% 0.076
late 38.2% 33.2% 40.2%
SSc activity index ≥3 (n = 3557) 20.0% 12.8% 22.9% <0.001
DLCO, % predicted (mean, SD) (n = 2909) 62.0 ± 20.2 67.4 ± 19.8 59.9 ± 20.0 <0.001
FVC, % predicted (mean, SD) (n = 2239) 87.5 ± 21.8 94.9 ± 20.9 84.4 ± 21.5 <0.001
FVC:DLCO ratio (n = 2072) 1.5 ± 0.5 1.5 ± 0.5 1.5 ± 0.5 n.s.
FEV-1, % predicted (mean, SD) (n = 2239) 86.2 ± 19.9 90.7 ± 19.0 84.2 ± 20.0 <0.001
TLC, % predicted (mean, SD) (n = 2239) 85.0 ± 20.5 90.6 ± 20.1 82.6 ± 20.2 <0.001
History (n = 3755)
worsening of skin 18.2% 12.5% 20.6% <0.001
worsening of fingers 22.7% 20.7% 23.6% n.s.
esophageal symptoms 66.2% 65.0% 66.6% n.s.
stomach symptoms 25.9% 22.1% 27.5% <0.001
intestinal symptoms 24.9% 24.2% 25.2% n.s.
arterial hypertension 23.2% 23.7% 23.0% n.s.
renal crisis 2.0% 1.7% 2.1% n.s.
dyspnoea 17.3% 12.2% 19.4% <0.001
worsening of cardiopulmonary manifestations 19.1% 14.8% 20.9% <0.001
palpitations 27.9% 23.8% 29.5% <0.001
Raynaud’s present 96.7% 96.1% 97.0% n.s.
NYHA class (n = 2426)
I 44.0% 49.9% 41.6%
II 38.7% 37.8% 39.0% <0.001
III 15.2% 10.1% 17.3%
IV 2.1% 2.1% 2.1%
Laboratory measures (n = 1346 –,648)
ANA+ 94.9% 95.6% 94.6% n.s.
ACA+ 21.9% 38.6% 15.1% <0.001
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groups p < 0.001). The same trend was seen in the fre-
quency of restrictive defects with the lowest rates in
patients in the never IS group (36%) and an increasing
frequency of 46.3% in group II and 61.0% in group III
(both p < 0.001).
Specific types of IS display minimal influence on the
course of lung function
Follow-up documentation ranging from 1 month to
13 years was available in 73.6% of patients with SSc-ILD.
Change in lung function over time was analysed in the
respective subgroups of patients with <50%, 50–75% and
>75% of FVC or DLCO predicted at treatment initiation
and are shown in Fig. 4.
The group starting with < 50% of predicted FVC had the
steepest decline in FVC (Fig. 4a). Here, GCs had negative
multiplicative effects (Fig. 4c), thus there was even worse
deterioration. In comparison, the group starting between
50 and 75% of predicted FVC had a less steep decline
(Fig. 4a), with a positive additive effect in ACA-positive
patients (Fig. 4b), but at the same time a negative multi-
plicative effect, meaning they started at higher FVC levels
but had a steeper decline. Here, in patients in the never IS
group a positive multiplicative effect was seen, indicating
a less steep decline. The group starting with > 75% of pre-
dicted FVC had only a slight decline in FVC (Fig. 4a, b)
with a negative additive effect in Scl70-positive patients
but at the same time a positive multiplicative effect
Table 1 Characteristics of patients with SSc-ILD never or ever using immunosuppressive therapy (Continued)
Total Never used IS therapy Ever used IS therapy P value
SCL70+ 48.8% 36.4% 53.8% <0.001
U1 RNP+ 6.4% 2.9% 7.9% <0.001
RNA+ 4.5% 4.1% 4.7% n.s.
PM-Scl+ 4.5% 3.7% 4.9% n.s.
CRP elevation 27.5% 18.5% 31.3% <0.001
CK elevation 9.3% 5.8% 10.7% <0.001
Proteinuria 6.4% 5.7% 6.7% n.s.
Hypocomplementemia 6.0% 4.9% 6.4% n.s.
ESR mm/h (mean, SD) 25.8 ± 20.7 23.7 ± 17.6 26.7 ± 21.7 0.048
Conduction blocks (n = 3451) 14.1% 12.8% 14.6% n.s.
Pulmonary hypertension (n = 3451) 23.2% 22.7% 23.3% n.s.
Diastolic function abnormal (n = 3363) 24.3% 21.1% 25.5% 0.008
Pericardial effusion (n = 2227) 12.6% 13.2% 12.4% n.s.
Ground glass opacification (n = 2014) 41.1% 30.3% 45.5% <0.001
PFT restrictive defect (n = 3457) 45.9% 35.6% 49.9% <0.001
Echo
LVEF (%) (n = 2095) 61.4 ± 6.2 62 ± 6.6 61.8 ± 6.5 0.005
PAPsys (mmHg) (n = 1835) 33 ± 14.9 32.4 ± 12.7 32.6 ± 13.4 n.s.
Right heart catheter
RVSP (mmHg) (n = 96) 46.8 ± 21.9 40.5 ± 17.9 42.5 ± 19.3 n.s.
PAPmean (mmHg) (n = 146) 36.2 ± 15.4 28.5 ± 12.0 30.8 ± 13.5 0.003
PVR (dyn · sec · cm-5) (n = 94) 541.5 ± 498 213.5 ± 258.1 328.6 ± 391.2 0.001
PWP (mmHg) (n = 113) 12.1 ± 7.0 12.2 ± 9.6 12.2 ± 9.0 n.s.
CI (l/min/m2) (n = 100) 2.8 ± 0.6 3.3 ± 1.1 3.1 ± 1.0 0.021
6 MWD
6 MWD (m) (n = 551) 444.9 ± 129.6 421.3 ± 123.8 428.1 ± 125.9 0.021
O2 saturation at rest (n = 457) 96 ± 6.3 95.9 ± 4.3 96.0 ± 5.0 n.s.
O2 saturation at exercise (n = 389) 92.9 ± 8.0 92.2 ± 8.0 92.4 ± 8.0 n.s.
BMI body mass index, mRSS modified Rodnan skin score, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, FEV-1 forced
expiratory volume in one second, TLC total lung capacity, NYHA New York Heart Association, ANA anti-nuclear antibodies, ACA anti-centromere antibodies, SCL70
anti-topoisomerase I antibody, U1 RNP U1-small nuclear ribonucloprotein particle, RNA ribonucleic acid antibody, PM SCL polymyositis scleroderma antibody, CRP
C-reactive protein, CK creatin kinase, ESR erythrocyte sedimentation rate, PFT pulmonary function test, LVEF left ventricular ejection fraction, PAPsys systolic pulmonary arterial
pressure, RVSP right ventricular systolic pressure, PAPmean mean pulmonary arterial pressure, PVR pulmonary vascular resistance, PWP pulmonary wedge pressure, CI cardiac
index, 6 MWD 6 minute walk distance, n.s. not significant
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(Fig. 4c), meaning they started at lower FVC levels but
had a flatter rate of decline. Here again, there were posi-
tive multiplicative effects in patients in the never IS group
or in those receiving GCs, indicating less or no decline or
even slight improvement.
Within the group starting with < 50% of predicted
DLCO the overall course was represented by a slightly
improving slope (Fig. 4b). Compared to that general
trend, CYC and MMF had negative additive effects,
meaning their course was following the same slope, but
on a lower level, while ACA positivity had a positive
additive effect, hence the course was on a higher level
(Fig. 4d). In patients starting with DLCO values between
50 and 75% of predicted the overall trend was of slight
Fig. 1 Frequencies of immunosuppressants ever used and highest therapy combination ever used per patient. GC glucocorticoids, CYC
cyclophosphamide, AZA azathioprine, MTX methotrexate, MMF mycophenolate mofetil, RTX rituximab, DPA D-penicillamine, a-TNF anti-tumour
necrosis factor, IMA imatinib
Fig. 2 Monotherapies (Mono) and combinations of immunosuppressants ever used, percentages are based on the number of patients. Treatment
regimens with frequencies <0.5% were omitted. GC glucocorticoids, CYC cyclophosphamide, AZA azathioprine, MTX methotrexate, MMF mycophenolate
mofetil, RTX rituximab, DPA D-penicillamine, a-TNF anti-tumour necrosis factor, IMA imatinib
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deterioration (Fig. 4b), with a negative additive effect of
TNF inhibitors, again meaning it already started at a
lower level but had the same gradient of deterioration.
Here, ACA had a slightly negative multiplicative effect,
meaning DLCO courses had a steeper decrease than the
general trend, while in patients in the never IS group a
positive multiplicative effect was seen, meaning a flatter
decrease (Fig. 4b, d), with a positive additive effect of
Scl70 positivity and a negative additive effect of GCs.
There was a negative multiplicative effect of MMF,
meaning an even steeper decrease than the general
trend, while there was a positive multiplicative effect in
patients in the never IS group (Fig. 4d), meaning less de-
cline or even slight improvement compared to the over-
all trend.
Adjusted for potential confounders and initial FVC
or DLCO value no other medications than GCs,
MMF, or “never IS” showed multiplicative effects on
the course of lung function divergent from the
general trend of the entire patient population. CYC
and TNF inhibitors had only additive effects, pointing
toward lower initial DLCO or FVC values in these
Fig. 3 Patients grouped according to severity of lung function combined with the respective immunosuppression (IS) and clinical parameters. never IS
patients who had never taken immunosuppressant drugs, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, SB single
breath, MTX methotrexate, GC glucocorticoid, AZA azathioprine, MMF mycophenolate mofetil, CYC cyclophosphamide, PFT pulmonary function test,
NYHA New York Heart Association, ACA anti-centromere antibodies, SCL70 anti-topoisomerase I antibody, CRP C-reactive protein
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patients, but no differing time trends compared to pa-
tients on other treatments.
Discussion
Our analysis of observational data describes current IS
strategies in patients with SSc-ILD from the EUSTAR
cohort. It shows clusters of clinical characteristics corre-
lated with IS choices and identifies factors that might in-
fluence future IS decisions.
A large proportion of patients with SSc-ILD did not
receive IS despite having dcSSc (34% of patients), active
scleroderma pattern on nail fold capillaroscopy (40% of
patients) and Valentini disease activity index (VDAI) ≥3
(12% of patients). On average these patients have longer
disease duration and show fewer signs of alveolitis on
HRCT. These characteristics may suggest that the great-
est decline in lung function has already happened and
stabilisation of lung function in the absence of active
inflammation is expected without any further IS medi-
cation [22], or they might represent patients with over-
all benign disease courses. In our analysis, positive
trends in lung function over time - especially in pa-
tients starting with 50–75% of predicted FVC - support
this notion. It contrasts with a scleroderma lung study
showing a mild 12-month decline in FVC of 4.2%,
and in DLCO of 8.2%, irrespective of disease duration
[1]. On the other hand our data are in agreement
with a study documenting that FVC values within the
first 3 years after disease onset strongly predict SSc-
ILD outcome [24].
GCs were used most frequently in 58% of the patients
in high proportions and even at dosages >10 mg/day and
>20 mg/day. This comes as a surprise and has to be
questioned, as the effect of GCs on lung function was
marginal at best and only slightly positive in patients
with > 75% of predicted FVC who might as well continue
Fig. 4 Change in lung function over all patients distinguished in three categories of values at the start of specific therapy (or at baseline for
patients who never took immunosuppressant therapy (never IS)) assessed by forced vital capacity (FVC) (a) and diffusing capacity of the lung for
carbon monoxide (DLCO) (b). Effects of different therapies on change in FVC (c) and change in DLCO (d) compared to the overall trend within
these three categories, adjusted for differences in sex, age, disease duration, extent of skin involvement and initial FVC or DLCO value, respectively.
Additive effects indicate the same slope shifted to a higher (+) or lower (-) level; positive multiplicative effects indicate a steeper rising or less declining
slope; negative multiplicative effects indicate a stronger declining slope. CYC cyclophosphamide, MMF mycophenolate mofetil, TNF tumor necrosis
factor inhibitor, GC glucocorticoid, MTX methotrexate, AZA azathioprine, IS immunosuppression
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without any IS at all. Furthermore, it is well-established
that this treatment regimen is associated with higher
rates of infection and scleroderma renal crisis [25]. Of
note, patients receive combinations of GC with MTX,
AZA, MMF or CYC regardless of lung function parame-
ters or NYHA class. Collectively our data show that
combining GCs with another IS therapy reflects the
standard of care in many centres worldwide.
The second most frequently used therapy was CYC, as
recommended by the EUSTAR guidelines for patients
with severe and progressive SSc-ILD. Two meta-analyses
failed to show a significant benefit of CYC on SSc-ILD
on lung function tests [26]. However, a statistically non-
relevant improvement might still represent a patient-
relevant effect on quality of life as reflected by the Short
Form-36 (SF-36) data evaluated within the first sclero-
derma lung study [4]. In our analysis, patients treated
with CYC monotherapy or CYC/GC started with the
worst DLCO values, worst NYHA class, highest frequen-
cies of restrictive defects and PH, and the highest mRSS.
More than 60% of these patients showed signs of active
inflammation reflected by high ESR, CRP elevation or
ground glass opacifications on HRCT. Stratification of
these patients by their starting values did not result
in differences in the slope of DLCO or FVC values
compared to all other patients. Interestingly, Becker
et al. describe the highest SSc-ILD response rates
assessed by FVC and DLCO in patients with low
FVC values prior to CYC therapy [27] indicating a
potential for reversal of fibrosis.
MMF, often regarded as potential maintenance therapy
in SSc-ILD, was used as monotherapy in moderate or -
combined with GC - severe lung impairment, in our
analysis. A prospective open-label trial on MMF de-
scribes early and significant improvement in DLCO,
non-significant improvement in FVC and reduction in
ground glass opacifications in five patients with disease
duration between 1.5 and 3 years [28]. A meta-analysis
argues along these lines, suggesting that MMF may sta-
bilise lung function [29]; however, the superiority of
MMF compared to CYC was not verified [7]. The very
recent randomized controlled, double-blind, parallel
group trial comparing MMF with oral CYC shows sig-
nificant improvement in pre-specified measures of lung
function over 2 years. It did not reach its primary end-
point, i.e. MMF to be more effective than CYC; however,
MMF had a better side-effect profile [8].
An uncontrolled study of AZA maintenance therapy
after 1-year induction with CYC showed stabilising ef-
fects of AZA in SSc-ILD, but involved only 13 patients
[30]. Retrospective data on 36 patients with SSc-ILD
comparing oral CYC with AZA shows significant effects
of AZA on DLCO and FVC, yet no effects of CYC [12].
Our data cannot confirm this as AZA had only a very
slightly positive effect on DLCO in patients starting with
DLCO >75%, thus being almost equal to the effect of
“never IS”.
Studies analyzing the effects of MTX on SSc-ILD are
rare. This might be due to the fact that ILD is one of the
possible side effects of MTX and hence physicians might
be hesitant to prescribe it to patients with SSc-ILD. In-
deed, there is one study showing no effects of MTX on
lung function despite trends towards positive effects on
the mRSS [31]. However, this study was small (n = 29)
and covered a relatively short timeframe (24 weeks). A
study with 11 patients taking MTX describes subjective
improvement in dyspnoea in 5 patients, no change in
another 5 and worsening in 1 patient [32]. In our data,
MTX was used in patients that resembled those of the
never IS group except for higher mRSS and more fre-
quent ground glass opacifications. Comparing MTX +
GC to MTX alone displayed significant differences in
mRSS, DLCO, FVC, FEV-1 and rates of ground glass
opacifications. Nevertheless, its effect on the course of
PFTs was negligible.
Overall, our data describe treatment patterns in
patients with SSc-ILD that are used across European
centres yet are only partially in accordance with
EUSTAR recommendations. Most clinicians chose inten-
sive IS in active lung disease. Common choices were not
only CYC+/-GC as recommended by current guidelines,
but also MMF +GC. None of the specific types of IS
was clearly superior to another in influencing the course
of lung function in any DLCO or FVC group. The only
positive trends seen were in patients in the never IS
group and patients taking GC, starting with > 75% of
predicted FVC, and in the never IS group, patients tak-
ing AZA and MTX starting with > 75% of predicted
DLCO all had a reduced rate of deterioration over time.
Thus, if carefully monitored for changes in lung func-
tion, patients with SSc-ILD with only small PFT impair-
ment might benefit from on-demand IS instead of
ongoing IS.
Our study has some limitations: The retrospective
design leaves us with some missing data, reducing the
large number of patients within this data set to small
groups when addressing specific questions of immuno-
suppressive treatment. Furthermore, changes in the pre-
scription pattern might be missed, and data on when
and why the immunosuppressive treatment was changed
are lacking. Additional prospective data are urgently
warranted. The prospective observational trial of the
Seventh Framework Programme (FP7) project “DeSSci-
pher” (a study to decipher the optimal management of
systemic sclerosis) launched in 2012 will allow assess-
ment of the dynamics of SSc-ILD-related treatment pat-
terns in terms of escalation and de-escalation and to
evaluate their efficacy.
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Conclusions
IS is broadly prescribed in SSc-ILD. Clusters of clinical
and functional characteristics guide individualised treat-
ment. The data favour differential decision-making
pointing either to watchful waiting and close monitoring
in the early stages or start of immunosuppressive treat-
ment in patients with SSc-ILD and moderately impaired
lung function. Advantages of specific IS are difficult to
depict due to confounding by indication. Data do not
support liberal use of GC in SSc-ILD.
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